Michelle Ross is the CIO of Stempoint Capital where she runs a biotech fund and she joins us once again now. It's good to see you. >> Very good to see you too.>> A reason to have a smile. Yeah. In in this space is what do you think of what Krinsky says.Is it meaningful. >> It's uh it's very unique set of circumstances that that have led us to this point. And I think what we saw even last week was pretty dynamic in the sense of how much some of these names traded up on the back of an announcement by the admi ...

Core Viewpoint - uniQure's stock experienced a significant surge of approximately 250% following positive results from its gene therapy for Huntington's disease, but the Adhishthana Principles suggest a more cautious outlook for investors [1][11]. Company Journey - uniQure has undergone an 18-phase Adhishthana cycle, currently in Phase 17, which is characterized by a historical pattern of forming a Cakra between Phases 4 and 8, typically indicating bullish trends [2]. - The stock initially formed its Cakra in Phase 4 but broke down during Phase 8, leading to a bearish signal known as the Move of Pralaya, resulting in a decline from $60 to $5 over more than 1,400 days [4][6]. Current Outlook - In Phase 17, the principles advise against new trades due to a weak Guna Triad and lack of a clear bullish setup, raising concerns about the sustainability of the recent price spike [9]. - The stock has already broken its Cakra, indicating potential fundamental issues, and has announced a $200 million underwritten public offering, further complicating the outlook [10]. Investor Outlook - While the medical data regarding Huntington's disease is promising, the Adhishthana cycle indicates that the recent rally may not be sustainable, suggesting that investors should wait for clearer signals before making new investments [11].